Drug Profile
MK 2748
Alternative Names: MK-2748Latest Information Update: 12 Apr 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 27 Aug 2012 Merck & Co appears to discontinue recruitment in its phase I trial for Hepatitis C in Moldova, and begins recruiting in Lithuania (NCT01593735)
- 31 May 2012 Phase-I clinical trials in Hepatitis C in Lithuania (PO)
- 31 May 2012 Phase-I clinical trials in Hepatitis C in Moldova (PO)